David Chen

Experience

• Advising LianBio in a number of in-licensing initiatives to develop and commercialize products for China, including deals with MyoKardia and BridgeBio Pharma Affiliates, Navire Pharma and QED Therapeutics.
• Advising Zai Lab in a number of in-licensing initiatives to develop and commercialize products for China.
• Advising Innovent Biologics in various in-licensing and out-licensing arrangements, including its development collaboration with MD Anderson Cancer Center.
• Advising NetEase, the leading China-based internet technology company providing on-line services centred on content, community, communications and commerce, in multiple matters including its investment in, and licensing of, Minecraft for China from Mojang.
• Advising Alibaba Group on the high-level intellectual property aspects of a number of matters, including its strategic partnership with Richemont and joint venture with YOOX Net-A-Porter Group to bring luxury retail e-commerce offerings to Chinese consumers.
• Advised a US-based global telecoms leader on a number of high-level enforcement mandates linked to patent rights in China.
• Advised a US multinational pharmaceutical company to engage another multinational pharma to promote a major diabetes product in China.
• Advised a US multinational pharmaceutical company in its collaboration with a Chinese biotech to develop AI algorithms for disease diagnosis.
• Advised a US-based medical technology manufacturer and distributor of medical devices, medical instrument systems and reagents on major intellectual property matters.
• Advised a consortium of investors in a going-private transaction involving Shangpharma, one of the largest Chinese life sciences services providers.
• Regularly advises biotechs to in-license drug assets for development and commercialization in China.
• Regularly advises and counsels multinational companies on China data protection and privacy compliance.